AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20012448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training (LLRT) with blood flow restriction (BFR) at 25% 1 RM
Number of subjects: 16
Study 20012448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training (LLRT) with blood flow restriction (BFR) at 50% 1 RM
Number of subjects: 16
Study 20012448 — intervention group
Group type: COMPARATOR
Intervention: Low-load resistance training (LLRT) with unrestricted blood flow
Number of subjects: 16
Study 18519324 — intervention group
Group type: EXPERIMENTAL
Intervention: Early motion group (mobilization within two weeks)
Number of subjects: 60
Study 18519324 — intervention group
Group type: COMPARATOR
Intervention: Late motion group (mobilization at six weeks)
Number of subjects: 60
Study 18519324 — intervention group
Group type: EXPERIMENTAL
Intervention: Early motion group
Number of subjects: 60
Study 18519324 — intervention group
Group type: COMPARATOR
Intervention: Late motion group
Number of subjects: 60
Study 15793272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT) combined with asthma education (AE)
Number of subjects: 48
Study 15793272 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 48
Study 12590626 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychogeriatric case management
Number of subjects: 86
Study 12590626 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners with specialist psychogeriatric consultation
Number of subjects: 86
Study 12590626 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study 10594293 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Skin Protectant (TSP)
Number of subjects: 50
Study 8912130 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ticarcillin and clavulinic acid (Timentin) pre-ERCP (group I)
Number of subjects: 156
Study 8912130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ticarcillin and clavulinic acid (Timentin) plus 3 days of oral amoxycillin and clavulinic acid (Augmentin) (group II)
Number of subjects: 156
Study 1811329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizoral cream containing ketoconazole
Number of subjects: 56
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: FU + ME
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: FU + ME + VC
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: FU + ME + DC
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: FU + ME + VC + DC
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: FU I.V. + HU P.O.
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all treatments)
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C and D (DC containing)
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment D
Number of subjects: 472
Study 7039814 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (FU + ME)
Number of subjects: 472
Study 31189978 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 353
Study 31189978 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 353
Study 30307270 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 0
Study 30307270 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative study designs and methods
Number of subjects: 0
Study 26467358 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (1 x 50 mg)
Number of subjects: 100
Study 26467358 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (2 x 12.5 mg)
Number of subjects: 100
Study 24838434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm of a randomized controlled study
Number of subjects: 1342
Study 22205496 — intervention group
Group type: EXPERIMENTAL
Intervention: Budiodarone 400 mg BID
Number of subjects: 72
Study 22205496 — intervention group
Group type: EXPERIMENTAL
Intervention: Budiodarone 600 mg BID
Number of subjects: 72
Study 22205496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20976388 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser λ 830 nm, 40 mW, 5J/cm²
Number of subjects: 40
Study 20976388 — intervention group
Group type: COMPARATOR
Intervention: Placebo application (0 J/cm²)
Number of subjects: 40
Study 17239324 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonists
Number of subjects: 0
Study 17239324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a 5-HT3 antagonist, steroids, and aprepitant
Number of subjects: 0
Study 15598679 — intervention group
Group type: EXPERIMENTAL
Intervention: AA/CHO supplement
Number of subjects: 13
Study 15598679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 13
Study 12753445 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 0.5 ml.kg‐1
Number of subjects: 2
Study 12753445 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.5 ml.kg‐1 with 1 microg x kg‐1 neostigmine
Number of subjects: 2
Study 9930771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training with lecture and videotape review
Number of subjects: 24
Study 7569819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound treatment
Number of subjects: 72
Study 7569819 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatment
Number of subjects: 72
Study 2142589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (group E, n = 10)
Number of subjects: 20
Study 2142589 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (group D, n = 10)
Number of subjects: 20
Study 7389058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CTX) 100 mg/day continuously
Number of subjects: 74
Study 7389058 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADM) 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day
Number of subjects: 74
Study 31272912 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-harm surveillance system
Number of subjects: 2259
Study 27457790 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide-resin-honey based cough syrup
Number of subjects: 150
Study 27457790 — intervention group
Group type: COMPARATOR
Intervention: Carbocysteine syrup
Number of subjects: 150
Study 25412569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 82
Study 25412569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 82
Study 23797047 — intervention group
Group type: EXPERIMENTAL
Intervention: SCE teaching with dermoscopy tutorial and a dermatoscope (Cohort 2)
Number of subjects: 288
Study 23797047 — intervention group
Group type: COMPARATOR
Intervention: SCE teaching only (Cohort 1)
Number of subjects: 288
Study 21755833 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM analysis (EXTEM_CFT)
Number of subjects: 30
Study 21755833 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM analysis (INTEM_CFT)
Number of subjects: 30
Study 21755833 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM analysis (PLT/INTEM)
Number of subjects: 30
Study 21755833 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM analysis (FIB/MCF_FIBTEM)
Number of subjects: 30
Study 19933083 — intervention group
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab) plus docetaxel
Number of subjects: 0
Study 19933083 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 0
Study 16478844 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention group receiving medical care, asthma education, and problem-solving therapy (n = 89)
Number of subjects: 175
Study 16478844 — intervention group
Group type: COMPARATOR
Intervention: Comparison group receiving medical care alone (n = 86)
Number of subjects: 175
Study 12776011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 11096044 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined conventional treatment and sorbent suspension dialysis (6-hour treatment)
Number of subjects: 41
Study 11096044 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 41
Study 9375591 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine treatment starting at 10 mg/day, gradually increased to a mean dose of 97 mg/day
Number of subjects: 58
Study 8262686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine and H2-receptor antagonists (cimetidine, ranitidine)
Number of subjects: 21
Study 2993147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 116
Study 2993147 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 116
Study 28946540 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 45
Study 28946540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 45
Study 28946540 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Number of subjects: 45
Study 25730597 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 84
Study 26417001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy (AHT) for 5 years
Number of subjects: 150
Study 26417001 — intervention group
Group type: COMPARATOR
Intervention: No AHT (control)
Number of subjects: 150
Study 23518209 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial reduction orthokeratology (PR ortho-k)
Number of subjects: 52
Study 23518209 — intervention group
Group type: COMPARATOR
Intervention: Spectacle-wearing control
Number of subjects: 52
Study 21609167 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed program of laboratory trainings and practice in PHC centers
Number of subjects: 0
Study 21609167 — intervention group
Group type: COMPARATOR
Intervention: Skills laboratory training
Number of subjects: 0
Study 19785251 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit problem-solving skills training program using a metacomponential approach
Number of subjects: 33
Study 19785251 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive training approach (control)
Number of subjects: 33
Study 16674618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscope
Number of subjects: 100
Study 16674618 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 100
Study 15080818 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 246
Study 15080818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 11264141 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxymetacaine-fluorescein (PROX-FLU)
Number of subjects: 0
Study 11264141 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine-fluorescein (LIG-FLU)
Number of subjects: 0
Study 9278212 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (non-specific adenosine antagonist)
Number of subjects: 0
Study 9278212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (adenosine reuptake inhibitor)
Number of subjects: 0
Study 9278212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8020521 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 200 mgI/ml
Number of subjects: 100
Study 8020521 — intervention group
Group type: COMPARATOR
Intervention: iopamidol 200 mgI/ml
Number of subjects: 100
Study 2532444 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.010 mg/kg
Number of subjects: 32
Study 2532444 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0.005 mg/kg
Number of subjects: 32
Study 810268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal betamethasone valerate
Number of subjects: 40
Study 810268 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 40
Study 31724354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 104
Study 31724354 — intervention group
Group type: COMPARATOR
Intervention: Western medication (conjugated estrogens and medroxyprogesterone acetate)
Number of subjects: 104
Study 28323173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) + Optimal Pharmacological Therapy (OPT)
Number of subjects: 293
Study 28323173 — intervention group
Group type: COMPARATOR
Intervention: Optimal Pharmacological Therapy (OPT)
Number of subjects: 293
Study 25288560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (dog walking strategy)
Number of subjects: 49
Study 25288560 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 25049048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary medium chain fatty acids (MCFA) supplementation (60 grams/day, mainly C8:0, C10:0)
Number of subjects: 12
Study 25049048 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid supplementation
Number of subjects: 12
Study 22731889 — intervention group
Group type: EXPERIMENTAL
Intervention: Active attention training program (directing attention away from threat)
Number of subjects: 79
Study 22731889 — intervention group
Group type: COMPARATOR
Intervention: Placebo attention training program (probe appeared with equal frequency in threatening and neutral faces)
Number of subjects: 79
Study 21029815 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak cardiac troponin-T (TnT)
Number of subjects: 1237
Study 21029815 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase-MB (CK-MB)
Number of subjects: 1237
Study 21029815 — intervention group
Group type: EXPERIMENTAL
Intervention: Final infarct size on SPECT scan
Number of subjects: 1237
Study 18790668 — intervention group
Group type: EXPERIMENTAL
Intervention: Home TV-channel providing educational materials (Intervention group)
Number of subjects: 214
Study 18790668 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up by cardiologists and HF-nurses (Control group)
Number of subjects: 214
Study 16195255 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 144
Study 16195255 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 144
Study 12594415 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bionator
Number of subjects: 0
Study 12594415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination headgear
Number of subjects: 0
Study 12594415 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment until permanent dentition
Number of subjects: 0
Study 10376260 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/cc MMC
Number of subjects: 50
Study 10376260 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/cc MMC
Number of subjects: 50
Study 9066364 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (iron chelator) for 10 months
Number of subjects: 1
Study 8101903 — intervention group
Group type: EXPERIMENTAL
Intervention: Acridine orange leucocyte cytospin (AOLC) test
Number of subjects: 0
Study 8101903 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein test
Number of subjects: 0
Study 8101903 — intervention group
Group type: COMPARATOR
Intervention: Nitroblue tetrazolium test
Number of subjects: 0
Study 3460737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg) with breakfast
Number of subjects: 12
Study 3460737 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (300 mg) fasting
Number of subjects: 12
Study 29511018 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting (PS)
Number of subjects: 660
Study 29511018 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stent technique
Number of subjects: 660
Study 27651908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery perfusion with oxygenated blood (n=30)
Number of subjects: 90
Study 27651908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery perfusion with histidine‐tryptophan‐ketoglutarate (HTK) solution (n=29)
Number of subjects: 90
Study 27651908 — intervention group
Group type: COMPARATOR
Intervention: No pulmonary perfusion (n=31)
Number of subjects: 90
Study 25915979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporting Compression (SC) tights
Number of subjects: 19
Study 22418699 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus gefitinib
Number of subjects: 141
Study 22418699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus gefitinib
Number of subjects: 141
Study 20390292 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 9) - unilateral plantar-flexor muscles fatigue
Number of subjects: 18
Study 20390292 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9) - standing rest period
Number of subjects: 18
Study 18194595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 190
Study 18194595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 15933485 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (n = 560)
Number of subjects: 1391
Study 15933485 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine/Paroxetine (n = 298)
Number of subjects: 1391
Study 15933485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 496)
Number of subjects: 1391
Study 12848396 — intervention group
Group type: EXPERIMENTAL
Intervention: Health technology assessment (HTA) initiatives
Number of subjects: 0
Study 12848396 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10321525 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 60
Study 10321525 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone
Number of subjects: 60
Study 10321525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BSS)
Number of subjects: 60
Study 8932119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Powder Device (DPD)
Number of subjects: 27
Study 8932119 — intervention group
Group type: COMPARATOR
Intervention: Metered Dose Inhaler (MDI)
Number of subjects: 27
Study 8333805 — intervention group
Group type: COMPARATOR
Intervention: Blacks
Number of subjects: 704
Study 8333805 — intervention group
Group type: COMPARATOR
Intervention: Whites
Number of subjects: 704
Study 8333805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 704
Study 3108794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day of perioperative prophylaxis with cefoperazone sodium
Number of subjects: 109
Study 3108794 — intervention group
Group type: COMPARATOR
Intervention: 5 days of perioperative antibiotic prophylaxis with cefoperazone sodium
Number of subjects: 109
Study 30056616 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted/rural kiR curriculum
Number of subjects: 2781
Study 30056616 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adapted/urban kiR curriculum (high delivery quality)
Number of subjects: 2781
Study 30056616 — intervention group
Group type: COMPARATOR
Intervention: Non-adapted/urban kiR curriculum (low delivery quality)
Number of subjects: 2781
Study 30056616 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2781
Study 27225652 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention (Take Care of You - TCOY)
Number of subjects: 0
Study 27225652 — intervention group
Group type: COMPARATOR
Intervention: Comparable intervention focusing on problematic alcohol use only
Number of subjects: 0
Study 27225652 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 24688181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rules of Two (Ro2)
Number of subjects: 150
Study 24688181 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Test (ACT)
Number of subjects: 150
Study 24688181 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment by patients
Number of subjects: 150
Study 24688181 — intervention group
Group type: COMPARATOR
Intervention: Evaluation of static lung function
Number of subjects: 150
Study 22057307 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-lesson classroom-based intervention (The Fourth R)
Number of subjects: 196
Study 22057307 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 196
Study 20657857 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (AVD) with video eyeglasses
Number of subjects: 120
Study 20657857 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide sedation
Number of subjects: 120
Study 18245800 — intervention group
Group type: EXPERIMENTAL
Intervention: Various experimental treatments (specific treatments not detailed)
Number of subjects: 52
Study 18245800 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (general quality indicators assessed)
Number of subjects: 52
Study 15880062 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1052
Study 12578788 — intervention group
Group type: COMPARATOR
Intervention: TTT alone
Number of subjects: 60
Study 12578788 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT + ICG
Number of subjects: 60
Study 10100144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on days 1 and 8; Gemcitabine 1000 mg/m2 on days 1 and 8; Cisplatin 75 mg/m2 on day 8, repeated every 21 days for a maximum of six cycles.
Number of subjects: 31
Study 10100144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine, gemcitabine, and cisplatin combination therapy
Number of subjects: 31
Study 8915032 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide (8-9 mg/kg/day) in drinking water
Number of subjects: 0
Study 8915032 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide (10 mg/kg) i.p. for 3 days
Number of subjects: 0
Study 8915032 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide (8-9 mg/kg/day) with rhIL-1beta (4.0 microg/kg) i.p. daily for 5 days
Number of subjects: 0
Study 8915032 — intervention group
Group type: COMPARATOR
Intervention: rhIL-1beta (4.0 microg/kg) i.p. daily for 5 days
Number of subjects: 0
Study 1745715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.0, 0.6, 0.13, 0.25, and 0.5 mg; total cumulative dose: 0.94 mg)
Number of subjects: 9